Home monitoring of patients with atrial fibrillation
Authors:
O. Ošmera; A. Bulava
Authors place of work:
Kardiocentrum Nemocnice České Budějovice, a. s.
1; Zdravotně sociální fakulta, Jihočeská univerzita v Českých Budějovicích
2
Published in the journal:
Kardiol Rev Int Med 2011, 13(3): 167-173
Summary
Home Monitoring is an advanced telemonitoring system used in clinical cardiology practice in the Czech Republic during ambulatory monitoring of patients with implantable devices. The percentage of patients with atrial fibrillation, which can be both basic and complicating disease, is increasing in this population. The presence of some kinds of implantable devices offers the possibility of a remote monitoring use in more efficient management of patients with atrial fibrillation. Through Home Monitoring system health care can be individualized, asymptomatic clinical events can be detected earlier and thus prevent their negative impacts.
Keywords:
home monitoring – telemonitoring – atrial fibrillation – heart failure
Zdroje
1. Paré G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base. J Am Med Inform Assoc 2007; 14: 269–277.
2. Masella C, Zanaboni P, Di Stasi F et al. Assessment of a remote monitoring system for implantable cardioverter defibrillators. J Telemed Telecare 2008; 14: 290−294.
3. Ošmera O, Bulava A. Telemedicína – objev třetího tisíciletí? Cor Vasa 2010; 52: 55−61.
4. J. Lipoldová, M. Novák. Dálkové monitorování implantabilních kardiostimulátorů a kardioverterů-defibrilátorů. Kardiol Rev 2006; 8: 129–139.
5. Ricci RP, Morichelli L, Santini M. Home monitoring remote control of pacemaker and implantable cardioverter defibrillator patients in clinical practice: impact on medical management and health-care resource utilization. Europace 2008; 10: 164−170.
6. Wilkoff B, Auricchio A, Brugada J et al. Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA); American College of Cardiology (ACC); American Heart Association (AHA); European Society of Cardiology (ESC); Heart Failure Association of ESC (HFA); Heart Failure Society of America (HFSA). HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace 2008; 10: 707−725.
7. Bytešník J, Čihák R. Arytmie v medicínské praxi. 1. vyd. Praha: Triton 1999: 60–61.
8. Lévy S, Camm AJ, Saksena S et al. Working Group on Arrhythmias, Working Group on Cardiac Pacing of the European Society of Cardiology, North American Society of Pacing and Electrophysiology. International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 2003; 5: 119–122.
9. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med 1994; 154: 2254]. Arch Intern Med 1994; 154: 1449–1457.
10. Miyasaka Y, Barnes ME, Petersen RC et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 2007; 28: 1962–1967.
11. Dries DL, Exner DV, Gers JB et al. Atrial fibrillation is associated with an increased risk form mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695–703.
12. Hamer ME, Blumenthal JA, McCarthy EA et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994; 74: 826–829.
13. Lurie KG, Iskos D, Fetter J et al. Prehospital discharge defibrillation testing in ICD recipients: a prospective study based on cost analysis. Pacing Clin Electrophysiol 1999; 22 (1 Pt 2): 192–196.
14. Glotzer TV, Hellkamp AS, Zimmerman J et al. MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614–1619.
15. Capucci A, Santini M, Padeletti L et al. Italian AT500 Registry Investigators. Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. J Am Coll Cardiol 2005; 46: 1913–1920.
16. Glotzer T, Daoud EG, Wyse DG et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474–480.
17. Varma N, Stambler B, Chun S. Detection of atrial fibrillation by implanted devices with wireless data transmission capability. Pacing Clin Electrophysiol 2005; 28 Suppl 1: S133–S136.
18. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices trough Home Monitoring technology improves detection and clinical management of atrial fibrilation. Europace 2009; 11: 54−61.
19. Schmitt C, Montero M, Melichercik J. Significance of supraventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators. Pacing Clin Electrophysiol 1994; 17 (3 Pt 1): 295–302.
20. Cesario DA et al. Atrial fibrillation and outcomes in a large cohort of CRT recipients: results from the ALTITUDE study. J Am Coll Cardiol 2011; 57: 153.
21. Theuns DA, Klootwijk AP, Simoons ML et al. Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. Am J Cardiol 2005; 95: 271–274.
22. Moss AJ, Zareba W, Hall WJ et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.
23. Fauchier L, Sadoul N, Kouakam C et al. Potential cost savings by telemedicine-assisted long-term care of implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol 2005; 28 (Suppl 1): S255−S259.
24. Res JC, Theuns DA, Jordaens L. The role of remote monitoring in the reduction of inappropriate implantable cardioverter defibrillator therapies. Clin Res Cardiol 2006; 95 (Suppl 3): III17−21.
25. Boriani G, Gasparini M, Landolina M et al. Clinical Service cardiac centres. Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail 2011; 10. [Epub ahead of print]
26. Zareba W, Steinberg JS, McNitt S et al. MADIT II Investigators. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm 2006; 3: 631–637.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2011 Číslo 3
Najčítanejšie v tomto čísle
- Antiarythmic treatment from the point of view of recent recommendations for the treatment of patients with atrial fibrillations
- Chronic cardiac failure with non-compact cardiomyopathy in a middle-aged woman
- Antithrombotic treatment from the point of view of new guidelines for the management of atrial fibrillation
- Home monitoring and implants